PHS
ADAP

PFM Health Sciences’s Adaptimmune Therapeutics ADAP Stock Holding History

PFM Health Sciences’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,871,969
Closed -$2.62M – 67
2024
Q4 		$2.62M Sell
4,871,969
-5,128,818
-51% -$3.74M 0.16% 68
2024
Q3 		$9.5M Sell
10,000,787
-519,444
-5% -$589K 0.54% 40
2024
Q2 		$10.3M Buy
10,520,231
+97,096
+0.9% +$107K 0.51% 47
2024
Q1 		$16.5M Hold
10,423,135
– – 0.77% 43
2023
Q4 		$8.27M Hold
10,423,135
– – 0.5% 47
2023
Q3 		$8.13M Buy
10,423,135
+2,065,893
+25% +$1.73M 0.38% 57
2023
Q2 		$7.73M Buy
8,357,242
+2,364,671
+39% +$2.82M 0.3% 62
2023
Q1 		$6.53M Buy
5,992,571
+1,149,061
+24% +$1.78M 0.29% 63
2022
Q4 		$7.07M Sell
4,843,510
-4,477,074
-48% -$7.25M 0.25% 71
2022
Q3 		$10M Buy
9,320,584
+210,804
+2% +$387K 0.36% 64
2022
Q2 		$15.5M Buy
9,109,780
+6,735,106
+284% +$11.6M 0.59% 52
2022
Q1 		$4.89M Sell
2,374,674
-826,392
-26% -$2.23M 0.18% 62
2021
Q4 		$12M Sell
3,201,066
-1,202,508
-27% -$5.47M 0.41% 55
2021
Q3 		$22.8M Buy
4,403,574
+775,674
+21% +$3.48M 0.67% 50
2021
Q2 		$15.5M Buy
3,627,900
+1,126,597
+45% +$5.47M 0.48% 56
2021
Q1 		$13.3M Sell
2,501,303
-193,466
-7% -$1.11M 0.41% 58
2020
Q4 		$14.5M Buy
2,694,769
+1,845,329
+217% +$10M 0.51% 61
2020
Q3 		$6.78M Buy
+849,440
New +$7.43M 0.31% 70
2015
Q4 		– Sell
-1,002,953
Closed -$12M – 68
2015
Q3 		$12M Buy
1,002,953
+37,438
+4% +$529K 0.34% 56
2015
Q2 		$17.7M Buy
+965,515
New +$16.6M 0.45% 61

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PFM Health Sciences's ADAP Position: Q1 2025 in Review

PFM Health Sciences sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 4,871,969 shares — an estimated $2.62M sold.

PFM Health Sciences first reported a position in ADAP in Q2 2015 and held it in 20 quarters. The position peaked at $22.8M in Q3 2021. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • PFM Health Sciences reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PFM Health Sciences sold 4,871,969 Adaptimmune Therapeutics shares in Q1 2025, an estimated $2.62M.
  • PFM Health Sciences first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 20 quarters.
  • PFM Health Sciences's Adaptimmune Therapeutics position peaked at $22.8M in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on PFM Health Sciences's 13F filing for Q1 2025, filed 15 May 2025.